JP2017538671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538671A5 JP2017538671A5 JP2017521577A JP2017521577A JP2017538671A5 JP 2017538671 A5 JP2017538671 A5 JP 2017538671A5 JP 2017521577 A JP2017521577 A JP 2017521577A JP 2017521577 A JP2017521577 A JP 2017521577A JP 2017538671 A5 JP2017538671 A5 JP 2017538671A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- sdab
- pharmaceutical composition
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 7
- 238000002965 ELISA Methods 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 238000003018 immunoassay Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102100030708 GTPase KRas Human genes 0.000 claims 4
- 238000011200 topical administration Methods 0.000 claims 4
- 239000012491 analyte Substances 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000004811 liquid chromatography Methods 0.000 claims 3
- 238000004949 mass spectrometry Methods 0.000 claims 3
- 239000007922 nasal spray Substances 0.000 claims 3
- 229940097496 nasal spray Drugs 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 238000013518 transcription Methods 0.000 claims 3
- 230000035897 transcription Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 102200006539 rs121913529 Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019149269A JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067908P | 2014-10-23 | 2014-10-23 | |
| US62/067,908 | 2014-10-23 | ||
| US201562148656P | 2015-04-16 | 2015-04-16 | |
| US62/148,656 | 2015-04-16 | ||
| US201562188353P | 2015-07-02 | 2015-07-02 | |
| US62/188,353 | 2015-07-02 | ||
| US201562210795P | 2015-08-27 | 2015-08-27 | |
| US62/210,795 | 2015-08-27 | ||
| PCT/US2015/057223 WO2016065323A2 (en) | 2014-10-23 | 2015-10-23 | Single domain antibodies directed against intracellular antigens |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019062231A Division JP6670963B2 (ja) | 2014-10-23 | 2019-03-28 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019149269A Division JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538671A JP2017538671A (ja) | 2017-12-28 |
| JP2017538671A5 true JP2017538671A5 (cg-RX-API-DMAC7.html) | 2018-11-29 |
Family
ID=55761757
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521577A Pending JP2017538671A (ja) | 2014-10-23 | 2015-10-23 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019062231A Active JP6670963B2 (ja) | 2014-10-23 | 2019-03-28 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019149269A Active JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021105631A Active JP6986180B2 (ja) | 2014-10-23 | 2021-06-25 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021192139A Active JP7195400B2 (ja) | 2014-10-23 | 2021-11-26 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019062231A Active JP6670963B2 (ja) | 2014-10-23 | 2019-03-28 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019149269A Active JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021105631A Active JP6986180B2 (ja) | 2014-10-23 | 2021-06-25 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021192139A Active JP7195400B2 (ja) | 2014-10-23 | 2021-11-26 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Country Status (24)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3209685T (lt) | 2014-10-23 | 2019-08-26 | Singh Molecular Medicine, Llc | Antikūnai su vienu duomenu, nukreipti prieš viduląstelinius antigenus |
| US20180072815A1 (en) | 2014-10-23 | 2018-03-15 | Singh Biotechnology, Llc | Single Domain Antibodies Directed Against Intracellular Antigens |
| US20170267784A1 (en) * | 2014-10-23 | 2017-09-21 | Singh Molecular Medicine, Llc | Single domain antibodies directed against intracellular antigens |
| IL254577B2 (en) | 2015-03-31 | 2023-11-01 | Vhsquared Ltd | polypeptides |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| CN107427577A (zh) | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| US10292951B2 (en) | 2015-09-01 | 2019-05-21 | First Wave Bio, Inc. | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
| TWI746473B (zh) | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
| CA3007997A1 (en) * | 2015-12-10 | 2017-06-15 | City Of Hope | Cell penetrating cyanine-coupled antibodies |
| WO2018060453A1 (en) | 2016-09-30 | 2018-04-05 | Vhsquared Limited | Compositions |
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP7130274B2 (ja) | 2017-12-22 | 2022-09-05 | ロフィバイオ インコーポレイテッド | 細胞内浸透能を有する抗ｓｔａｔ３二重特異性抗体およびこれを含む薬学的組成物 |
| KR20190076354A (ko) * | 2017-12-22 | 2019-07-02 | 주식회사 로피바이오 | 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물 |
| JP2021523115A (ja) * | 2018-05-04 | 2021-09-02 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 炎症性疾患または障害を治療するための方法および組成物 |
| KR102101561B1 (ko) * | 2018-07-25 | 2020-04-20 | 가톨릭대학교 산학협력단 | 신생혈관 표적용 조영제 조성물 및 이의 제조방법 |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| US12247079B2 (en) | 2019-06-21 | 2025-03-11 | Sorriso Pharmaceuticals, Inc. | Polynucleotides encoding, and method of making, a polypeptide comprising a VHH which binds interleukin-receptor (IL-7R) |
| AU2020296979A1 (en) | 2019-06-21 | 2022-02-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| CN110357965A (zh) * | 2019-06-24 | 2019-10-22 | 浙江大学 | 一种突变型kras特异性抗体及其制备方法 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| KR20220153604A (ko) | 2020-03-11 | 2022-11-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 가공된 바이러스 입자를 사용하는 유전자 전달을 위한 방법 및 조성물 |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| CN115215939B (zh) * | 2021-04-14 | 2025-09-23 | 中山大学 | 一种融合蛋白及其制备方法与应用 |
| MX2024000309A (es) * | 2021-07-07 | 2024-04-09 | Singh Biotechnology Llc | Supresión de la uveítis mediante anticuerpos de dominio único. |
| WO2023028589A2 (en) * | 2021-08-27 | 2023-03-02 | Singh Biotechnology, Llc | Therapeutic single domain antibody |
| JP2024546914A (ja) | 2021-12-15 | 2024-12-26 | インテリウス・バイオセラピューティクス・インコーポレイテッド | 偽型ウイルス粒子、それを含む組成物、及びそれらの使用 |
| WO2024003873A1 (en) * | 2022-06-30 | 2024-01-04 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Single variable domain antibodies against tumor necrosis factor-alpha |
| US12252512B2 (en) | 2022-07-25 | 2025-03-18 | Interius Biotherapeutics, Inc. | Mutated polypeptides, compositions comprising the same, and uses thereof |
| IL322228A (en) | 2023-02-04 | 2025-09-01 | Momenta Pharmaceuticals Inc | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| WO2025004683A1 (ja) * | 2023-06-30 | 2025-01-02 | 国立大学法人大阪大学 | がん検査方法及びがん治療剤 |
| WO2025027511A1 (en) | 2023-07-30 | 2025-02-06 | Janssen Biotech, Inc. | Molecules that bind to mutant calreticulin and uses thereof |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| WO2025109518A1 (en) | 2023-11-21 | 2025-05-30 | Janssen Biotech, Inc. | Methods for treatment of myeloproliferative neoplasms |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| DE69334095T2 (de) * | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
| FR2706486B1 (fr) * | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| WO2001006989A2 (en) | 1999-07-27 | 2001-02-01 | Abgenix, Inc. | Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| US6277974B1 (en) * | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
| DE10019157A1 (de) | 2000-04-18 | 2001-11-15 | Stefan Duebel | Verfahren zum Einbringen von Liganden in lebende Zellen |
| US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| US20040052762A1 (en) | 2001-09-10 | 2004-03-18 | Hua Yu | Stat3 agonists and antagonists and therapeutic uses thereof |
| HUP0400775A2 (en) * | 2000-12-29 | 2007-05-02 | Bio Technology General Corp | Specific human antibodies for selective cancer therapy |
| AU2003219277A1 (en) * | 2002-03-14 | 2003-09-29 | Medical Research Council | Intracellular antibodies |
| GB0226727D0 (en) * | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| SI1578446T1 (sl) * | 2002-11-07 | 2015-07-31 | Immunogen, Inc. | Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| AU2003286002B2 (en) * | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
| US7638122B2 (en) | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
| US20050226863A1 (en) | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| US20100143371A1 (en) | 2006-10-31 | 2010-06-10 | Zhenping Zhu | Intrabodies |
| CA2588106A1 (en) * | 2007-05-18 | 2008-11-18 | Nrc - Institute For Biological Sciences | Single-domain antibodies and heavy chain antibody against egfr and uses thereof |
| EP2008666A1 (en) | 2007-06-29 | 2008-12-31 | Institut Pasteur | Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications |
| US20110195509A1 (en) | 2007-09-06 | 2011-08-11 | Drew Pardoll | Treatment of th17-mediated autoimmune disease via inhibition of stat 3 |
| JP2011526619A (ja) * | 2008-06-30 | 2011-10-13 | サイレンシード リミテッド | 局所ドラッグデリバリーシステム、その方法、および、その組成物 |
| EP2143735A1 (en) * | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| US20100092470A1 (en) * | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| US20130177979A1 (en) | 2010-06-22 | 2013-07-11 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for cell permeable stat3 inhibitor |
| JP6170940B2 (ja) * | 2011-12-20 | 2017-07-26 | アダエラータ、リミテッド パートナーシップＡｄａｅｒａｔａ， Ｌｉｍｉｔｅｄ Ｐａｒｔｎｅｒｓｈｉｐ | Ｐｃｓｋ９の阻害剤としての単一ドメイン抗体 |
| EP3483273A1 (en) * | 2012-10-31 | 2019-05-15 | Ionis Pharmaceuticals, Inc. | Cancer treatment |
| WO2014144148A1 (en) * | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Stabilized sos1 peptides |
| WO2014153495A2 (en) * | 2013-03-22 | 2014-09-25 | University Of Hawaii | Novel stat3 inhibitors |
| CN103368197B (zh) | 2013-07-15 | 2015-11-25 | 国家电网公司 | 模块化多电平换流器的阀基控制设备和方法 |
| CN105658230B (zh) | 2013-08-29 | 2020-04-21 | 希望之城 | 细胞穿透缀合物及其使用方法 |
| EP2873680A1 (en) | 2013-11-13 | 2015-05-20 | F.Hoffmann-La Roche Ag | Oligopeptide and methods for producing conjugates thereof |
| EP2899208A1 (en) | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
| LT3209685T (lt) | 2014-10-23 | 2019-08-26 | Singh Molecular Medicine, Llc | Antikūnai su vienu duomenu, nukreipti prieš viduląstelinius antigenus |
-
2015
- 2015-10-23 LT LTEP15853465.1T patent/LT3209685T/lt unknown
- 2015-10-23 KR KR1020197026711A patent/KR102207382B1/ko active Active
- 2015-10-23 CA CA3052777A patent/CA3052777C/en active Active
- 2015-10-23 SM SM20190413T patent/SMT201900413T1/it unknown
- 2015-10-23 IL IL289769A patent/IL289769B2/en unknown
- 2015-10-23 MX MX2017003268A patent/MX379450B/es unknown
- 2015-10-23 AU AU2015335600A patent/AU2015335600B2/en active Active
- 2015-10-23 SI SI201530789T patent/SI3209685T1/sl unknown
- 2015-10-23 LT LTEP19165430.0T patent/LT3590962T/lt unknown
- 2015-10-23 RS RS20211519A patent/RS62694B1/sr unknown
- 2015-10-23 KR KR1020187004337A patent/KR102023289B1/ko active Active
- 2015-10-23 CN CN201580056968.9A patent/CN106852148B/zh active Active
- 2015-10-23 SI SI201531763T patent/SI3590962T1/sl unknown
- 2015-10-23 DK DK15853465.1T patent/DK3209685T3/da active
- 2015-10-23 BR BR122020006907A patent/BR122020006907B8/pt active IP Right Grant
- 2015-10-23 ES ES15853465T patent/ES2731876T3/es active Active
- 2015-10-23 ES ES19165430T patent/ES2900253T3/es active Active
- 2015-10-23 PT PT15853465T patent/PT3209685T/pt unknown
- 2015-10-23 BR BR122020006918A patent/BR122020006918B8/pt active IP Right Grant
- 2015-10-23 PL PL15853465T patent/PL3209685T3/pl unknown
- 2015-10-23 HR HRP20191056TT patent/HRP20191056T1/hr unknown
- 2015-10-23 SM SM20210695T patent/SMT202100695T1/it unknown
- 2015-10-23 KR KR1020197026708A patent/KR102207381B1/ko active Active
- 2015-10-23 EP EP15853465.1A patent/EP3209685B1/en active Active
- 2015-10-23 US US14/922,098 patent/US9663570B2/en active Active
- 2015-10-23 JP JP2017521577A patent/JP2017538671A/ja active Pending
- 2015-10-23 PT PT191654300T patent/PT3590962T/pt unknown
- 2015-10-23 US US14/922,081 patent/US20160115247A1/en not_active Abandoned
- 2015-10-23 US US14/922,093 patent/US9695234B2/en active Active
- 2015-10-23 HU HUE15853465A patent/HUE047601T2/hu unknown
- 2015-10-23 CA CA2962275A patent/CA2962275C/en active Active
- 2015-10-23 DK DK19165430.0T patent/DK3590962T3/da active
- 2015-10-23 EP EP21192390.9A patent/EP4006052A1/en active Pending
- 2015-10-23 KR KR1020177006630A patent/KR101831123B1/ko active Active
- 2015-10-23 RS RS20190750A patent/RS59063B1/sr unknown
- 2015-10-23 CA CA3114318A patent/CA3114318A1/en active Pending
- 2015-10-23 CN CN202010738353.7A patent/CN111848793B/zh not_active Expired - Fee Related
- 2015-10-23 PL PL19165430T patent/PL3590962T3/pl unknown
- 2015-10-23 TW TW104134979A patent/TWI664289B/zh active
- 2015-10-23 BR BR122020006914A patent/BR122020006914B8/pt active IP Right Grant
- 2015-10-23 US US14/922,100 patent/US9546211B2/en active Active
- 2015-10-23 BR BR112017008165A patent/BR112017008165B8/pt active IP Right Grant
- 2015-10-23 HU HUE19165430A patent/HUE057605T2/hu unknown
- 2015-10-23 EP EP19165430.0A patent/EP3590962B1/en active Active
- 2015-10-23 HR HRP20211889TT patent/HRP20211889T1/hr unknown
- 2015-10-23 RU RU2017116710A patent/RU2017116710A/ru not_active Application Discontinuation
- 2015-10-23 WO PCT/US2015/057223 patent/WO2016065323A2/en not_active Ceased
-
2017
- 2017-03-06 IL IL250961A patent/IL250961B/en unknown
- 2017-03-10 MX MX2021001098A patent/MX2021001098A/es unknown
-
2019
- 2019-03-28 JP JP2019062231A patent/JP6670963B2/ja active Active
- 2019-06-28 AU AU2019204614A patent/AU2019204614B2/en not_active Ceased
- 2019-07-03 CY CY20191100706T patent/CY1122035T1/el unknown
- 2019-08-16 JP JP2019149269A patent/JP6928773B2/ja active Active
-
2021
- 2021-01-22 AU AU2021200416A patent/AU2021200416B2/en active Active
- 2021-06-25 JP JP2021105631A patent/JP6986180B2/ja active Active
- 2021-11-26 JP JP2021192139A patent/JP7195400B2/ja active Active
- 2021-12-09 CY CY20211101082T patent/CY1124867T1/el unknown
-
2022
- 2022-06-15 AU AU2022204167A patent/AU2022204167A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538671A5 (cg-RX-API-DMAC7.html) | ||
| RU2017116710A (ru) | Однодоменные антитела, направленные против внутриклеточных антигенов | |
| Hong et al. | Hepatic stellate cells express functional CXCR4: Role in stromal cell–derived factor‐1α–mediated stellate cell activation | |
| Wilkins et al. | IFITM1 is a tight junction protein that inhibits hepatitis C virus entry | |
| Deng et al. | STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib | |
| US20210024893A1 (en) | Medical uses of exosomes | |
| Saeedi-Boroujeni et al. | Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19 | |
| Deng et al. | Targeting transmembrane BAX inhibitor motif containing 1 alleviates pathological cardiac hypertrophy | |
| JP2016530323A5 (cg-RX-API-DMAC7.html) | ||
| JP2015506944A5 (cg-RX-API-DMAC7.html) | ||
| Suzukawa et al. | Leptin enhances ICAM-1 expression, induces migration and cytokine synthesis, and prolongs survival of human airway epithelial cells | |
| EA201100641A1 (ru) | Антитела к il-6 и их применение | |
| Guo et al. | Glycyrrhizic acid alleviates liver fibrosis in vitro and in vivo via activating CUGBP1-mediated IFN-γ/STAT1/Smad7 pathway | |
| JP2019504107A5 (cg-RX-API-DMAC7.html) | ||
| EA201991704A3 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EP3120142A2 (en) | Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer | |
| JP2021181450A (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| RU2013104039A (ru) | Способ идентификации пациента с повышенной вероятностью ответа на противораковую терапию | |
| Nkongolo et al. | The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA | |
| JP2019524706A5 (cg-RX-API-DMAC7.html) | ||
| Justinich et al. | The extracellular calcium-sensing receptor (CaSR) on human esophagus and evidence of expression of the CaSR on the esophageal epithelial cell line (HET-1A) | |
| Li et al. | Cellular communication network factor 1 promotes retinal leakage in diabetic retinopathy via inducing neutrophil stasis and neutrophil extracellular traps extrusion | |
| Kim et al. | xCT-mediated glutamate excretion in white adipocytes stimulates interferon-γ production by natural killer cells in obesity | |
| JP2012521549A5 (cg-RX-API-DMAC7.html) |